Navigation Links
Prodigy Health Supplier Partners with Stason Pharmaceuticals to Help Relieve U.S. Drug Shortages
Date:6/26/2012

AUSTIN, Texas, June 26, 2012 /PRNewswire/ -- Prodigy Health Supplier entered a Joint Venture with Stason Pharmaceuticals to bring a diverse line of quality generic pharmaceuticals to the U.S. market. This relationship represents a combined commitment to providing the highest quality generic drugs with a consistent supply and a competitive price.

The partnership supports robust research and development with 30 PhDs on staff and over 120 people in that department. Core generic therapeutic categories include oncology, central nervous system (CNS), cardiovascular and dermatologic indications. Delivery mechanisms for the drugs include capsules and oral solids as well as new delivery mechanisms.

Bryan Sanders, president of Prodigy Health Supplier, states, "Quality manufacturing in Stason will provide excellent long term value to our business as well as the generic pharmaceutical market. Three of our current registrations are found on the national FDA shortage list and we are dedicated to bringing these products to market as soon as possible to help alleviate this strain. There are 7 drugs in our present pipeline that will be released over the next two years and we are evaluating additional items on the shortage list for potential registration and production."

Prodigy Health Supplier Corporation (PHS), a privately held company, was established in 2001 and is based in Austin, Texas. Since inception PHS has been a consistent and dependable supplier in the bio-pharmaceutical industry and has grown into one of the leading suppliers of plasma derivatives and injectables in the United States. PHS launched their generics division in 2010 and partners with proven manufacturers to provide a strong portfolio of generic drugs to the U.S. market. More information about PHS can be found at www.phscorporation.com.

Stason Pharmaceuticals, Inc., established in 1994 and based in Irvine, CA is a privately-held, global pharmaceutical company involved in drug development, manufacturing, importation/exportation, licensing and marketing of both generic and branded products. The company's primary area of development is in the area of oncology, and supportive products for the treatment of side effects related to cancer therapy. Additional therapeutic areas include cardiovascular, central nervous system, autoimmune and endocrine disorders. Additional information about Stason can be found at www.stasonpharma.com.


'/>"/>
SOURCE Prodigy Health Supplier Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Prodigy Generics and eVenus Announce the Launch of Oncology Injectable Irinotecan.
2. HealthWarehouse.com and Northwest Physicians Network Partner to Provide Exclusive Discount Pharmacy Services to Patients
3. Double Helix Joins McCann Health
4. Prostate Cancer and Bone Health
5. HealthWarehouse.com Reports 82% Year-Over-Year Revenue Growth
6. Billians HealthDATA Expands Market Coverage to Include Physician Group Practices
7. Vocollect Healthcare Systems And Prime Care Technologies Bring AccuNurse Key Performance Metrics To Long-Term Care Providers Via primeVIEW Digital Dashboard
8. U.S. News & World Report and Pharmacy Times Announce "Top Recommended Health Products"
9. ZO Skin Health, Inc. Sues Third-Party Pirates Over Illegal Sales of its Products
10. Lifescript Launches New Online Asthma Health Center
11. Gateway Foundation Warns K2 is Bad News: K2 Poses Serious Health Risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... India , April 19, 2017 ... and Application, Forecast to 2022 report has covered and analysed ... statistics and information on market size, shares and growth factors. ... major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 28, 2017 , ... Accreditation Commission for Health Care (ACHC) ... America (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s ... Accreditation University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Getting enough sleep affects much more than ... (NSF), going just 19 hours without sleep can compromise motor reaction time, which can increase ... and Amica Insurance is sharing the following tips from the NSF to help you sleep ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery ... the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, ... patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... People are ... older people. “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa ... Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec Solutions ... Grove Foundation implement a Microsoft Dynamics GP solution that integrates to their PointClickCare ... that specializes in long-term care, Brooke Grove now has the capability to achieve ...
Breaking Medicine News(10 mins):